Sign in
Active, not recruitingPhase 1

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

Key facts

Who runs it
BioCryst Pharmaceuticals
Where
Chicago, Indianapolis, New Haven, Palo Alto, and San Diego, United StatesSee the 5 sitesAlso in 4 other countries, 7 sites
Trial code
Status
Active, not recruiting
Phase
Phase 1
People taking part
76 people enrolled
Started
26 Sept 2024
Expected to end
Feb 2027
Type of study
Interventional, 6 groups
Treatments tested
  • BCX17725
  • Placebo
Record updated
6 November 2026

Who can take part

Age
12 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Male or non-pregnant, non-lactating female aged 18 to 55 years, inclusive (Parts 1 and 2), 18 to 65 years, inclusive (Part 3), or 12 to 65 years, inclusive (Part 4)
  • Confirmed diagnosis of Netherton syndrome (Parts 3 and 4)
  • IGA score of ≥ 3 (Parts 3 and 4) and IASI score of ≥ 16 (Part 4)
  • BMI between 18 and 30 kg/m\^2, inclusive (Parts 1 and 2)
  • Estimated glomerular filtration rate (eGFR) of ≥ 90 mL/min/1.73 m\^2 (Parts 1 and 2) or ≥ 60 mL/min/1.73 m\^2 (Part 3)
  • Agree to follow the protocol contraception requirements from screening until 90 days after the last dose of study drug
  • In the opinion of the investigator, expected to adequately comply with all required study procedures and restrictions for the duration of the study

Where in United States

Also in 4 other countries, 7 sites

  • Northwestern Dermatology CTUChicago, United States
  • Dawes Fretzin Clinical Research Group, LLCIndianapolis, United States
  • Yale Center for Clinical InvestigationNew Haven, United States
  • Stanford University, School of MedicinePalo Alto, United States
  • Therapeutics Clinical ResearchSan Diego, United States

About the trial

What the trial wants to find out

This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when administered via multiple IV and/or SC doses through 12 weeks will be evaluated in adult and adolescent participants with Netherton syndrome.

The 6 groups in the trial

  • Part 1 - BCX17725 single doseTreatment being tested

    Participants randomized to BCX17725 will receive BCX17725 as a single dose in sequential ascending dose cohorts

    Treatment: BCX17725

  • Part 1 - placebo single doseTreatment being tested

    Participants randomized to placebo will receive placebo as a single dose

    Treatment: Placebo

  • Part 2 - BCX17725 multiple dosesTreatment being tested

    Participants randomized to BCX17725 will receive BCX17725 as multiple doses in sequential ascending dose cohorts

    Treatment: BCX17725

  • Part 2 - placebo multiple dosesTreatment being tested

    Participants randomized to placebo will receive placebo as multiple doses

    Treatment: Placebo

  • Part 3 - BCX17725 multiple dosesTreatment being tested

    Participants will receive BCX17725 as multiple doses

    Treatment: BCX17725

  • Part 4 - BCX17725 multiple dosesTreatment being tested

    Participants will receive BCX17725 as multiple doses

    Treatment: BCX17725

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome
Record updated
6 November 2026